← Back to Search

Diagnostic Imaging Techniques for Shoulder Osteoarthritis (UESOA Trial)

N/A
Waitlist Available
Led By Peter Lapner, MD, FRCSC
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults <60 years of age
Be between 18 and 65 years old
Must not have
>60 years of age
Pre-existing joint deformity (OA) cases greater than grade I (as per Samilson and Prieto)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5-years post-allocation
Awards & highlights
No Placebo-Only Group

Summary

This trial is investigating the development of shoulder OA.

Who is the study for?
This trial is for adults under 60 with shoulder osteoarthritis, specifically those showing more than 55% posterior humeral head subluxation on imaging. It's not suitable for individuals over 60, those with labral or rotator cuff issues, pre-existing joint deformities beyond grade I, neurological disorders of the upper limb, history of shoulder instability or trauma including fractures.
What is being tested?
The study aims to understand the causes and progression of shoulder osteoarthritis by using low-dose CT scans, T1Rho MRI imaging techniques and motion analysis to observe changes in the joint over time.
What are the potential side effects?
While this study involves diagnostic tests rather than treatments, potential side effects may include discomfort during motion analysis and exposure to radiation from CT scans. The MRI procedure is generally safe but may cause claustrophobia or discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am younger than 60 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am over 60 years old.
Select...
I have a joint deformity more severe than mild.
Select...
I have a rotator cuff injury.
Select...
I have had a shoulder injury or fracture before.
Select...
I have a nerve disorder affecting my arm.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5-years post-allocation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5-years post-allocation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Finite Element Analysis
Motion Analysis
Magnetic Resonance Imaging
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group 1: Early Degeneration ('Disease')Experimental Treatment3 Interventions
Those who have posterior subluxation of the humeral head and show early signs of degeneration in their shoulder.
Group II: Group 2: No Degeneration ('Healthy')Active Control3 Interventions
Those who have posterior subluxation of the humeral head and show no signs of degeneration.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Low-dose CT
2015
N/A
~60

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
575 Previous Clinical Trials
3,094,823 Total Patients Enrolled
University of OttawaOTHER
221 Previous Clinical Trials
269,589 Total Patients Enrolled
Peter Lapner, MD, FRCSCPrincipal InvestigatorThe Ottawa Hospital Research Institute

Media Library

Motion Analysis Clinical Trial Eligibility Overview. Trial Name: NCT04634773 — N/A
Shoulder Arthritis Research Study Groups: Group 1: Early Degeneration ('Disease'), Group 2: No Degeneration ('Healthy')
Shoulder Arthritis Clinical Trial 2023: Motion Analysis Highlights & Side Effects. Trial Name: NCT04634773 — N/A
Motion Analysis 2023 Treatment Timeline for Medical Study. Trial Name: NCT04634773 — N/A
~22 spots leftby Dec 2026